The record → Compounding & pharmacy tracker → Empower Pharmacy
Pharmacy file · FDA warning letter MARCS-CMS 738238 · Added 28 October 2026
Empower Pharmacy FDA warning letter: what it says, and who names Empower
On 18 September 2026, FDA issued warning letter MARCS-CMS 738238 to Empower Clinic Services, LLC dba Empower Pharmacy (Houston, TX), after inspecting its 503A facility from 3 to 14 November 2025. FDA says the pharmacy compounded semaglutide and tirzepatide products that appear to be essentially copies of FDA-approved drugs, regularly and in inordinate amounts, and that drugs intended to be sterile were made under insanitary conditions with CGMP violations.
The letter is addressed to the pharmacy. It is not an action against any telehealth brand, and it is not counted against any provider on this site. On our record, Amble Health, Henry Meds, Willow name or are linked to Empower Pharmacy as a fulfillment partner.
Primary source: FDA, Warning Letter MARCS-CMS 738238, Empower Clinic Services, LLC dba Empower Pharmacy (fda.gov) ↗
The document
What the letter says, point by point
| Issued | 18 September 2026 by FDA CDER, Office of Compounding Quality and Compliance (delivered by email) |
|---|---|
| Recipient | Empower Clinic Services, LLC dba Empower Pharmacy, 7601 N. Sam Houston Pkwy W., Ste. 100, Houston, TX 77064 |
| Inspection | 3–14 November 2025; Form FDA 483 issued 14 November 2025; firm responses dated 8 December 2025, 18 March 2026 and 30 April 2026 |
| 503A finding | Products including tirzepatide/niacinamide and semaglutide/cyanocobalamin appear to be essentially copies of FDA-approved semaglutide and tirzepatide, compounded regularly or in inordinate amounts; FDA calls the claimed differences pretextual given the volume |
| Prescriptions | Orders lacking any prescriber determination of significant difference, and significant-difference statements repeated verbatim across many records that FDA says may be pre-generated for selection, for example via third-party technology platforms |
| Sterility | Insanitary conditions for drugs intended to be sterile (adulterated under FD&C Act §501(a)(2)(A)): inadequate dynamic smoke studies of the ISO 5 area; media fills not run under the most challenging conditions |
| CGMP | Violations of 21 CFR 211.42, 211.113(b), 211.22 and 211.100(a) cited for the ineligible products (adulterated under §501(a)(2)(B)); also described as unapproved new drugs and misbranded under §502(f)(1) |
| Next step | Written response requested within 15 working days; FDA notes failure to address violations may lead to legal action including seizure and injunction |
| What it is not | Not a recall notice, not a court finding, and not addressed to any telehealth provider |
Who names Empower
3 telehealth providers on record name or are linked to Empower Pharmacy
Listed alphabetically. Each card links to the full dossier and to the provider’s own site. Naming a partner pharmacy does not mean every order ships from it; the pharmacy on your vial label is the record.
Context, not a recommendation
Compounded providers on record that do not name Empower
Compounded-only providers with no regulatory action on our record and a published all-in price, ordered by that price (lowest first). This is arithmetic, not a ranking of quality.
Straight answers
Questions this page answers
- Did the FDA send Empower Pharmacy a warning letter?
- Yes. FDA's Center for Drug Evaluation and Research issued warning letter MARCS-CMS 738238, dated 18 September 2026, to Empower Clinic Services, LLC dba Empower Pharmacy at 7601 N. Sam Houston Pkwy W., Ste. 100, Houston, TX 77064. It followed an FDA inspection from 3 to 14 November 2025 and a Form FDA 483 issued on 14 November 2025. FDA posted the letter on fda.gov; the page shows content current as of 22 September 2026.
- What does the Empower Pharmacy warning letter say about compounded semaglutide and tirzepatide?
- FDA says the facility compounded products including tirzepatide/niacinamide and semaglutide/cyanocobalamin that appear to be essentially copies of FDA-approved semaglutide and tirzepatide, regularly and in inordinate amounts, and that the volume suggests the claimed differences from the approved products are pretextual. It also points to prescriptions with no prescriber determination of a significant difference, and to significant-difference statements repeated verbatim across many records, which FDA says may be pre-generated for selection by the prescriber.
- Does the letter say anything about sterility or manufacturing quality?
- Yes. FDA says drugs intended to be sterile were prepared, packed or held under insanitary conditions, citing inadequate dynamic smoke studies of the ISO 5 area and media fills not performed under the most challenging conditions, and lists CGMP violations including environmental monitoring, aseptic-process validation and quality-control-unit oversight. FDA says some corrective actions appear adequate, others could not be fully evaluated and others appear deficient. The firm was asked to respond in writing within 15 working days.
- Is my compounded GLP-1 from Empower Pharmacy unsafe or recalled?
- The letter does not announce a recall and does not report a tested defect in a specific shipped vial; it describes inspection observations and FDA's legal position. A warning letter is not a court finding, and the pharmacy can respond. The pharmacy printed on your own vial label is the authoritative record of where your medication came from. If you have questions about a medication you are taking, ask the prescriber on your telehealth account.
- Which GLP-1 telehealth providers use Empower Pharmacy?
- On this record, 3 of 128 providers name or are linked to Empower Pharmacy: Amble Health, Henry Meds, Willow. Naming a partner pharmacy does not mean every order ships from it. The letter is addressed to the pharmacy, not to these providers, and is not counted as an action against any of them.
See also: all disclosed 503A/503B pharmacies · the enforcement record against telehealth providers · who sells compounded GLP-1s · how we verify a claim
Source: GLP-1 Dossier Editorial Desk (2026), “Empower Pharmacy FDA Warning Letter MARCS-CMS 738238,” https://glp1dossier.com/empower-pharmacy-fda-warning-letter (Checked 16 November 2026). Primary document: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026